25/100B40.640
USD
-0.02
(-0.05%)
Market Open
Last updated: · Delayed 15 min
Roivant Sciences cash on hand 2019–2026What is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.
Roivant Sciences had 4.21B USD in cash and short-term investments on 30 September 2026, down 4.1% on a year before. At the end of fiscal year 2025 it had 4.30B USD.
Last updated 10 Nov 2026 · Next report 5 Feb 2027
Cash on hand
Growth
| Fiscal year | Period ending | Cash on hand | Growth | Total debt | Net cash |
|---|---|---|---|---|---|
| Latest quarter | 30 Sept 2026 | 4.21B | -4.06% | 106.57M | 4.10B |
| FY2025 | 31 Mar 2026 | 4.30B | -12.10% | 107.44M | 4.19B |
| FY2024 | 31 Mar 2025 | 4.89B | -25.29% | 100.17M | 4.79B |
| FY2023 | 31 Mar 2024 | 6.54B | +288.93% | 499.75M | 6.04B |
| FY2022 | 31 Mar 2023 | 1.68B | -18.37% | 481.40M | 1.20B |
| FY2021 | 31 Mar 2022 | 2.06B | -3.39% | 283.89M | 1.78B |
| FY2020 | 31 Mar 2021 | 2.13B | -2.41% | 244.98M | 1.89B |
| FY2019 | 31 Mar 2020 | 2.19B | — | 180.88M | 2.00B |
| Quarter | Period ending | Cash on hand | Growth on a year before | Total debt | Net cash |
|---|---|---|---|---|---|
| Q2 FY2026 | 30 Sept 2026 | 4.21B | -4.06% | 106.57M | 4.10B |
| Q1 FY2026 | 30 Jun 2026 | 3.84B | -14.68% | 107.15M | 3.73B |
| Q4 FY2025 | 31 Mar 2026 | 4.30B | -12.10% | 107.44M | 4.19B |
| Q3 FY2025 | 31 Dec 2025 | 4.53B | -11.98% | 207.44M | 4.32B |
| Q2 FY2025 | 30 Sept 2025 | 4.39B | -18.58% | 98.85M | 4.29B |
| Q1 FY2025 | 30 Jun 2025 | 4.50B | -20.77% | 99.69M | 4.40B |
| Q4 FY2024 | 31 Mar 2025 | 4.89B | -25.29% | 100.17M | 4.79B |
| Q3 FY2024 | 31 Dec 2024 | 5.15B | -22.85% | 100.31M | 5.05B |
| Q2 FY2024 | 17 Sept 2024 | 5.39B | +281.03% | 52.71M | 5.33B |
| Q1 FY2024 | 30 Jun 2024 | 5.68B | +294.89% | 379.06M | 5.30B |
| Q4 FY2023 | 31 Mar 2024 | 6.54B | +288.93% | 499.75M | 6.04B |
| Q3 FY2023 | 31 Dec 2023 | 6.67B | +335.60% | 506.58M | 6.16B |
| Q2 FY2023 | 30 Sept 2023 | 1.41B | — | 497.98M | 915.73M |
| Q1 FY2023 | 30 Jun 2023 | 1.44B | — | 492.64M | 946.72M |
| Q4 FY2022 | 31 Mar 2023 | 1.68B | — | 487.07M | 1.19B |
| Q3 FY2022 | 31 Dec 2022 | 1.53B | — | 479.64M | 1.05B |
Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet
Common questions about Roivant Sciences's cash
Source: Financial Modeling Prep